If you made any changes in Pure these will be visible here soon.

Research Output

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

Claessens, A. K. M., Erdkamp, F. L. G., Lopez-Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., Honkoop, A. H., de Graaf, H., Tjan-Heijnen, V. C. G., Bos, M. E. M. M. & Dutch Breast Canc Res Grp BOOG, 2 Jun 2020, In : Acta Oncologica. 59, 6, p. 713-722 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

Claessens, A. K. M., Timman, R., Busschbach, J. J., Bouma, J. M., Rademaker-Lakhai, J. M., Erdkamp, F. L. G., Tjan-Heijnen, V. C. G., Bos, M. E. M. M. & Dutch Breast Canc Res Grp BOOG, Feb 2020, In : Breast Cancer Research and Treatment. 179, 3, p. 677-685 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice

Claessens, A. K. M., Ibragimova, K. I. E., Geurts, S. M. E., Bos, M. E. M. M., Erdkamp, F. L. G. & Tjan-Heijnen, V. C. G., Sep 2020, In : Critical Reviews in Oncology/Hematology. 153, 12 p., 102988.

Research output: Contribution to journalReview articleAcademicpeer-review

Open Access